The bottleneck in scientific research is monkeys

Recently, Joinn Laboratories, China's leading preclinical testing company, announced surprising financial results. In the first half of the year, the company reported profits of 747.5 million yuan, surpassing its revenues of 703.8 million. This increase is largely due to the revaluation of its 'biological assets,' referring to monkeys used in research.

This phenomenon raises a crucial question: why are monkeys increasing in price, and why are they so essential in scientific research? As the demand for these primates in clinical trials grows, the supply has become limited, leading to a significant increase in their market value.

## Why it matters The shortage of monkeys in China is not just an economic issue for biotechnology companies; it also represents a serious obstacle to advancing medical research. Monkeys are vital for developing and testing new treatments, and their lack can delay the arrival of crucial innovations in public health.

## What we know Joinn Laboratories has seen an increase in the value of its biological assets due to the revaluation of monkey prices in the market. This situation has led the company to report positive financial results, despite not having sold more monkeys.

## What remains unclear It has not yet been confirmed how China plans to address this shortage of monkeys or if there are strategies underway to increase supply. Additionally, the specific factors leading to this price increase are not known, further complicating the situation for researchers.